93 reports of this reaction
1.6% of all DORZOLAMIDE HYDROCHLORIDE reports
#11 most reported adverse reaction
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is the #11 most commonly reported adverse reaction for DORZOLAMIDE HYDROCHLORIDE, manufactured by Micro Labs Limited. There are 93 FDA adverse event reports linking DORZOLAMIDE HYDROCHLORIDE to INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION. This represents approximately 1.6% of all 5,992 adverse event reports for this drug.
Patients taking DORZOLAMIDE HYDROCHLORIDE who experience inappropriate schedule of product administration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is a less commonly reported adverse event for DORZOLAMIDE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to inappropriate schedule of product administration, the following adverse reactions have been reported for DORZOLAMIDE HYDROCHLORIDE:
The following drugs have also been linked to inappropriate schedule of product administration in FDA adverse event reports:
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION has been reported as an adverse event in 93 FDA reports for DORZOLAMIDE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION accounts for approximately 1.6% of all adverse event reports for DORZOLAMIDE HYDROCHLORIDE, making it a notable side effect.
If you experience inappropriate schedule of product administration while taking DORZOLAMIDE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.